7 mm (range 5-8 mm) before surgery. Of the seven patients,
bony union of the fracture developed in six. At latest follow-up, two patients had neck pain associated with movement and limited range of rotational motion.
Direct repair under microendoscope is a new technique that improves bony union of displaced anterior arch of the atlas fractures.”
“Background: Although agonistic autoantibodies against type-1 angiotensin-II receptor (AT(1)-AA) are frequently detected in women with preeclampsia, the clinical significance of AT(1)-AA in association with epithelial ovarian cancer (EOC) has not been identified.
Methods: In an attempt to clarify this issue, we measured serum AT(1)-AA titer from EOC patients (n = 89) and healthy normal subjects (n selleck inhibitor = 55), correlated AT(1)-AA titer with EOC stage and grade, and demonstrated the effects of purified AT(1)-AA on migration of ovarian cancer cells and angiogenesis of chick embryo chorioallantoic membrane.
Results: We found that the AT(1)-AA titer
was significantly higher in EOC patients compared with healthy control subjects (1.77 +/- 0.28 vs. 0.35 +/- 0.05, P < 0.01). The positive rate was averaged by 72.1 +/- 2.5% in EOC patients and 15.5 +/- 1.5% in control (P < 0.01). Increased AT(1)-AA titer in EOC patients was associated with advanced stages and grades of EOC, and positively correlated with level of vascular endothelial growth factor (r = 0.855, P < 0.01). Furthermore, AT(1)-AA directly Selleck VX-661 stimulated migration of ovarian cancer cells and enhanced microvascular density of chick embryo chorioallantoic membrane. These AT(1)-AA-mediated effects were significantly blocked either by an autoantibody-neutralizing
peptide or an angiotensin II type I receptor antagonist, losartan.
Conclusion: Taken together, we found that a higher serum AT(1)-AA titer may be associated with advanced progression of EOC in patients and play an important role in development of EOC by promoting cancer cell migration and angiogenesis. These findings implicate that AT(1)-AA might be selected as a detectable biomarker and potential therapeutic target in diagnosis and treatment of EOC patients.”
“Twenty five human breast adipose tissue samples selleck products were collected in Porto Alegre. Brazil during 2004-2005 and analyzed for polybrominated diphenyl ethers (PBDEs) and polychlorinated biphenyls (PCBs). Sigma PBDE concentrations (sum of tri- to hepta-BDEs) ranged from 0.19 to 132 ng/g lipid with a median of 1.51 ng/g lipid. These concentrations are 3- to 100-times lower than those reported from other countries, with the exception of Japan, probably reflecting lower usage of PBDE-containing products or lower exposures to these chemicals. The predominant congener was BDE-47, followed by BDEs 99,183. 153 and 100. One individual in the dataset had about 70-times higher PBDE concentrations than the rest of the participants. Sigma PCB (sum of PCBs 118.